Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Institut Curie
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02028923CT.gov Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Ulcer Of Skin
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nepenthe (this asset) | Institut Curie | P3 | B · 60 |
| Desferrioxamine B | TauTona Group | P1/2 | CCC |
| ha35 | Nakhia Impex LLC | N/A | D |
| Hyaluronate | Nakhia Impex LLC | N/A | D |
| Arginine Butyrate | Susan P. Perrine | P2 | NR |
Other indications for Nepenthe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nepenthe in Chronic Ulcer Of Skin. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nepenthe-chronic-ulcer-of-skin
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →